Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
复制标题
放化疗治疗区域性胰腺癌：一项 II 期研究。
DOI：
10.1097/01.coc.0000037143.60502.54
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Shields,AnthonyF
中科院分区：
文献类型：
--
作者：
Al-Sukhun,Sana;Zalupski,MarkM;Ben-Josef,Edgar;Vaitkevicius,VainutisK;Philip,PhilipA;Soulen,Renate;Weaver,Donald;Adsay,Volkan;Heilbrun,LanceK;Levin,Kenneth;Forman,JefferyD;Shields,AnthonyF
在局部晚期胰腺癌中，化疗和放疗的使用正在增加，尽管鉴于几项当代试验报告的长期结果，肯定需要进一步改进。使用顺铂、阿糖胞苷、咖啡因和连续输注 (CI) 5-氟尿嘧啶 (5-FU)(PACE) 组合治疗晚期胰腺癌的令人鼓舞的结果促使开展一项使用 PACE 的 II 期研究，随后使用 5-FU CI 的外照射放疗 (PACE-RT) 治疗局部疾病。 41 名患者接受 PACE-RT 作为手术切除后的辅助治疗（21 名患者），或作为局部晚期不可切除疾病的主要治疗（20 名患者），并在治疗完成后重新评估切除情况。 PACE包括第1天顺铂100 mg/m 2 IV，阿糖胞苷2 g/m 2 IV每12小时×2剂量，以及每次阿糖胞苷剂量后皮下注射咖啡因400 mg/m 2 ；第 3 至 21 天，CI 给予 5-FU 250 mg/m 2/d。每 28 天重复一次循环。 2个周期的PACE后，放射治疗同时给予5-FU 200 mg/m 2/d。在辅助环境中，肿瘤床和引流淋巴结盆地分别接受 50.4 Gy 和 45 Gy。在新辅助治疗中，原发淋巴结和区域淋巴结将接受 39.6 Gy 的照射，然后对肿瘤总体积进行 8 NGy 的中子增强。光子治疗以每次分次 1.8 Gy 的剂量进行，中子治疗以每次分次 0.8 NGy 的剂量进行，每周 5 天。所有患者均可评估毒性和生存率。最常见的毒性是骨髓抑制，59% 的患者出现 III 至 IV 级中性粒细胞减少症。局部晚期和辅助治疗患者的中位生存时间分别为13.4个月和18.1个月，1年生存率分别为52%和65%。接受 PACE-RT 治疗的 20 名不可切除癌患者中，有 9 名的肿瘤已充分消退，符合探查的临床标准；其中三例出于治疗目的而被切除。这三名接受新辅助治疗后接受切除的患者的生存期分别为22.4、24.3和40个月。治疗方案是积极的，但耐受性中等。使用更新的、毒性较小的药物修改该方案可能会提供更好的结果并降低毒性。
In locally advanced pancreatic cancer, the utilization of chemotherapy and radiotherapy is increasing, although in view of the reported long-term results of several contemporary trials, further improvements are certainly needed. Encouraging results using the combination of cisplatin, cytarabine, caffeine, and continuous infusion (CI) 5-fluorouracil (5-FU)(PACE) for the treatment of advanced pancreatic carcinoma prompted a phase II study using PACE followed by external beam radiotherapy with CI of 5-FU (PACE-RT) for localized disease. Forty-one patients were treated with PACE-RT as adjuvant therapy after surgical resection (21 patients), or as primary therapy for locally advanced, unresectable disease (20 patients), with reevaluation for resection after completion of treatment. PACE consisted of cisplatin 100 mg/m 2 IV on day 1, cytarabine 2 g/m 2 IV every 12 hours× 2 doses, and caffeine 400 mg/m 2 subcutaneously after each cytarabine dose; and days 3 to 21, 5-FU 250 mg/m 2/d given by CI. Cycles were repeated every 28 days. After 2 cycles of PACE, radiation therapy was given concurrently with 5-FU at 200 mg/m 2/d. In the adjuvant setting, the tumor bed and the draining lymph node basin received 50.4 Gy and 45 Gy, respectively. In the neoadjuvant setting, the primary and regional lymph nodes were to receive 39.6 Gy followed by a neutron boost of 8 NGy to the gross tumor volume. Photon therapy was delivered at 1.8 Gy per fraction and neutron therapy at 0.8 NGy per fraction, 5 days a week. All patients were evaluable for toxicity and survival. The most common toxicity was myelosuppression, with grade III to IV neutropenia occurring in 59% of the patients. The median survival times in the locally advanced and adjuvant patients were 13.4 and 18.1 months, with 1-year survival rates of 52% and 65%, respectively. Nine of 20 patients receiving PACE-RT for unresectable carcinoma had sufficient tumor regression to meet clinical criteria for exploration; three were resected with curative intent. The survival of these three patients undergoing resection after neo-adjuvant therapy was 22.4, 24.3 and 40 months. The treatment program was active, but only moderately well tolerated. Modification of this regimen with newer, less toxic drugs may provide better results and reduced toxicity.
登录
查看更多内容
肺静脉闭塞性疾病：实体还是综合征？
DOI：
--
发表时间：
1976
期刊：
影响因子：
--
作者：
C. Wagenvoort
通讯作者：
C. Wagenvoort
临床原发性肺动脉高压：三种病理类型。
影响因子：
37.8
作者：
W. Edwards;J. Edwards
通讯作者：
J. Edwards
中年人肺静脉闭塞性疾病。
DOI：
10.1159/000194788
发表时间：
1985
期刊：
Respiration; international review of thoracic diseases
影响因子：
--
作者：
Glassroth,J;Woodford,DW;Carrington,CB;Gaensler,EA
通讯作者：
Gaensler,EA
肺静脉闭塞性疾病：肺动脉受累和文献综述。
影响因子：
3.3
作者：
C. Wagenvoort;N. Wagenvoort;T. Takahashi
通讯作者：
T. Takahashi
DOI：
--
发表时间：
1985
期刊：
British Journal of Diseases of the Chest
影响因子：
--
作者：
G. Canny;G. Arbus;G. Wilson;C. Newth
通讯作者：
C. Newth